NCT00423826

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Barbara Ann Karmanos Cancer Institute · Academic / Other
• Sex: All
• Age: 69 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil before the transplant may stop this from happening. PURPOSE: This clinical trial is studying how well umbilical cord blood stem cell transplant works in treating patients with hematologic cancer or other disease.

Detailed description

OBJECTIVES: Primary * Determine the efficacy of double umbilical cord blood stem cell transplantation using a conditioning regimen comprising lower doses of busulfan and fludarabine phosphate and low-dose total body irradiation, in terms of stem cell engraftment at 60 days post transplantation, in patients with hematologic cancer or other diseases. * Determine the merits of conducting a larger, comparative study of this regimen. Secondary * Determine mortality within 100 days of transplantation in these patients. OUTLINE: This is a pilot study. * Reduced-intensity conditioning regimen: Patients receive busulfan IV over 3 hours on days -9 to -8 and fludarabine phosphate IV on days -7 to -3. Patients then undergo low-dose total body irradiation on day 0. * Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV twice daily and mycophenolate orally or IV three times daily beginning on day -3. * CNS prophylaxis and/or treatment: Patients with a history of CNS involvement receive prophylactic cytarabine (Ara-C) intrathecally (IT) prior to transplant. Patients also undergo lumbar puncture (LP) to test for active CNS disease. Patients with cerebrospinal fluid positive for leukemia receive Ara-C IT every 2-3 days until a repeat LP shows no remaining leukemic cells. Three days after the last LP and after one final dose of Ara-C, patients begin the conditioning regimen. * Double umbilical cord blood (UCB) donor stem cell transplantation (SCT): Patients undergo double UCB donor SCT on day 0. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Conditions

• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Syndromes
• Precancerous Condition
• Secondary Myelofibrosis

Interventions

Type	Name	Description
DRUG	Busulfan	3 mg/kg intravenously over 3 hours
DRUG	Cytarabine	Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
DRUG	Fludarabine phosphate	25 mg/M2/day IV
DRUG	mycophenolate mofetil	Orally at the dose of 1 gm every 8 hours.
DRUG	tacrolimus	0.015 mg/kg IV every 12 hours by continuous infusion.
PROCEDURE	allogeneic hematopoietic stem cell transplantation	10 days post drug intervention
PROCEDURE	umbilical cord blood transplantation	10 days post drug intervention
RADIATION	total-body irradiation	10 days post drug intervention

Timeline

• Start date: 2007-01-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2007-01-18
• Last updated: 2016-02-29

Locations

1 site across 1 country: United States